Busulfan, Cyclophosphamide And Melphalan As Conditioning Regimen For Pediatric Patients With Aml In 1st Or 2nd Cr: A Retrospective Analysis From The Aieop Hsct Registry

Annalisa Ruggeri,Marco Zecca,Franca Fagioli,Adriana Balduzzi,Mattia Algeri,Manuela Tumino,Mimmo Ripaldi,Riccardo Masetti,Francesco Saglio, Attilio Rovelliand,Franco Locatelli

BLOOD（2018）

引用 0|浏览1

暂无评分

摘要

Allogeneic stem cell transplantation (HSCT) is largely adopted as post-remissional therapy in children with acute myeloid leukemia (AML) in first complete remission (CR1) but with high-risk characteristics (including high-risk cytogenetics or high levels of minimal residual disease at the end of induction therapy) or to rescue patients reaching CR2 after a previous relapse.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要